United Therapeutics (UTHR) CFO sells 10,000 shares after exercising options
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
UNITED THERAPEUTICS Corp CFO and Treasurer James Edgemond reported a series of insider transactions in the company’s common stock. On May 21, 2026, he exercised 10,000 stock options at an exercise price of $117.76 per share, converting them into common shares.
That same day, he executed multiple open-market sales totaling 10,000 shares at prices in the mid‑$560s, with trades reported at weighted average prices such as $566.12 and $563.12. The filing states these transactions were carried out under a Rule 10b5‑1 trading plan entered into on October 31, 2025, indicating they were pre‑scheduled.
After these transactions, Edgemond directly owns 28,876 shares of United Therapeutics common stock and holds 70,000 stock options following the 10,000‑share option exercise.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Net Seller: 10,000 shares ($5,641,130)
Net Sell
9 txns
Insider
EDGEMOND JAMES
Role
CFO AND TREASURER
Sold
10,000 shs ($5.64M)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option | 10,000 | $0.00 | -- |
| Exercise | Common Stock | 10,000 | $117.76 | $1.18M |
| Sale | Common Stock | 40 | $557.85 | $22K |
| Sale | Common Stock | 320 | $560.0275 | $179K |
| Sale | Common Stock | 920 | $562.0083 | $517K |
| Sale | Common Stock | 2,677 | $563.1242 | $1.51M |
| Sale | Common Stock | 2,081 | $564.1044 | $1.17M |
| Sale | Common Stock | 1,765 | $565.1028 | $997K |
| Sale | Common Stock | 2,197 | $566.1213 | $1.24M |
Holdings After Transaction:
Stock Option — 70,000 shares (Direct, null);
Common Stock — 28,876 shares (Direct, null)
Footnotes (1)
- This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on October 31, 2025. This transaction was executed in multiple trades at prices ranging from $559.99 to $560.04. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $561.51 to $562.39. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $562.63 to $563.59. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $563.63 to $564.61. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $564.64 to $565.60. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $565.64 to $566.48. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Key Figures
Shares sold: 10,000 shares
Option exercise size: 10,000 shares
Exercise price: $117.76 per share
+4 more
7 metrics
Shares sold
10,000 shares
Total common shares sold in open-market trades on May 21, 2026
Option exercise size
10,000 shares
Common shares acquired via stock option exercise on May 21, 2026
Exercise price
$117.76 per share
Strike price for 10,000 stock options exercised
Sale price example
$566.1213 per share
Weighted average price for a 2,197-share sale tranche
Post-transaction holdings
28,876 shares
Common shares directly owned by CFO after transactions
Remaining options
70,000 options
Stock options held after the 10,000-share exercise
Earliest sale price
$557.85 per share
Weighted average price for a 40-share sale tranche
Key Terms
Rule 10b5-1 trading plan, stock options, open-market sale, derivative security, +1 more
5 terms
Rule 10b5-1 trading plan regulatory
"This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
stock options financial
"This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan"
Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.
open-market sale financial
"transaction_action": "open-market sale""
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
derivative security financial
"transaction_code_description": "Exercise or conversion of derivative security""
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
weighted average price financial
"The price reported above reflects the weighted average price."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
FAQ
What insider transaction did United Therapeutics (UTHR) disclose for CFO James Edgemond?
United Therapeutics reported that CFO James Edgemond exercised 10,000 stock options and sold 10,000 common shares in open-market trades on May 21, 2026. The sales were executed at prices in the mid-$560s under a pre-arranged Rule 10b5-1 trading plan.
What stock options did the United Therapeutics (UTHR) CFO exercise in this Form 4 filing?
James Edgemond exercised 10,000 United Therapeutics stock options on May 21, 2026 at an exercise price of $117.76 per share. The options related to 10,000 underlying common shares and were originally scheduled to expire on March 15, 2027.